Well, I am for sure no mind reader, or have any other super connections to the GNBT management, so I cannot really answer your question truthfully as to what Todd explicitly meant with his statement that you are referring to.
With that said, however, I can only repeat myself in reminding you and everyone else here on the almost done deal and clearly laid out roll out plans regarding Excellegen that we've been told during the last CC in May already.
Dilution free loan money was promised to the Olaregen team and they sounded very confident to be able to generate double (and over the longer term tripple) digit millions of dollars in revenue with that jump start financing available.
That was all laid out very clearly to us in May, if I then read from Todd that they are moving forward on all fronts, I am clearly hoping, or almost expecting, to hear about significant money being generated on that front. Should that gag order finally be lifted and this assumption turns out to be true, I am sure that the sheer price will soon be in a much higher orbit.
The other obvious expectation that I guess we all have from Todd's statement is that they keep making progress on the vaccine development front. What does "moving forward" on this front mean? The IND application is approved and the clinical trials have already started? Just imagine what an impact such a PR would have, giving us good reasons for the CompleteSilence over the last couple of months, being finally cleared from all accusations and "Oh, by the way, we have successfully completed phase I clinical trials and are getting ready to start phase II" (ok, maybe a little far fetched and a lot of wishful thinking here!?)
But, assuming that at least the first post about Excellegen is true, the revenue pouring in works definitely end the dilution, and give them the opportunity to further broaden their base via Olaregen trials, or finally closing the AltuCell deal and providing additional funding for their research.
I am sure that the current situation looks significantly worse than it actually is, which is why - believe is or not - I did purchase another 10k shares yesterday at 0,085 €/share (equivalent to ~$ 0. 095/share).
Trust me, I cannot wait for this period of terrible uncertainty and speculation to end, and we all be updated from our management, but for the time being this is how I interpret Todd's words.
I hope this helps you and answers your question?
With that said, however, I can only repeat myself in reminding you and everyone else here on the almost done deal and clearly laid out roll out plans regarding Excellegen that we've been told during the last CC in May already.
Dilution free loan money was promised to the Olaregen team and they sounded very confident to be able to generate double (and over the longer term tripple) digit millions of dollars in revenue with that jump start financing available.
That was all laid out very clearly to us in May, if I then read from Todd that they are moving forward on all fronts, I am clearly hoping, or almost expecting, to hear about significant money being generated on that front. Should that gag order finally be lifted and this assumption turns out to be true, I am sure that the sheer price will soon be in a much higher orbit.
The other obvious expectation that I guess we all have from Todd's statement is that they keep making progress on the vaccine development front. What does "moving forward" on this front mean? The IND application is approved and the clinical trials have already started? Just imagine what an impact such a PR would have, giving us good reasons for the CompleteSilence over the last couple of months, being finally cleared from all accusations and "Oh, by the way, we have successfully completed phase I clinical trials and are getting ready to start phase II" (ok, maybe a little far fetched and a lot of wishful thinking here!?)
But, assuming that at least the first post about Excellegen is true, the revenue pouring in works definitely end the dilution, and give them the opportunity to further broaden their base via Olaregen trials, or finally closing the AltuCell deal and providing additional funding for their research.
I am sure that the current situation looks significantly worse than it actually is, which is why - believe is or not - I did purchase another 10k shares yesterday at 0,085 €/share (equivalent to ~$ 0. 095/share).
Trust me, I cannot wait for this period of terrible uncertainty and speculation to end, and we all be updated from our management, but for the time being this is how I interpret Todd's words.
I hope this helps you and answers your question?
4
